A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
← catalyst calendarNCT05568095 · readout ≤ 12 d
Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Gilead Sciences, Taiho Pharmaceutical Co., Ltd..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,040actual
Sites
168
Countries
Argentina, Australia, Brazil +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-21 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
- Drug: Domvanalimab — also filed as AB154
- Drug: Zimberelimab — also filed as AB122
- Drug: Capecitabine
- Drug: Fluorouracil
- Drug: Leucovorin
- Drug: Oxaliplatin
- Drug: Nivolumab
Primary outcome
what the primary-completion date above is the date OFOverall survival
measured From date of randomization until date of death from any cause (Approximately 15 months)]
Publications
- PMID 40341124 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed